A Phase 1/2 clinical trial to evaluate the combination of CG0070 with Atezolizumab in patients with various advanced solid tumors
Latest Information Update: 24 Sep 2021
At a glance
- Drugs Atezolizumab (Primary) ; Cretostimogene grenadenorepvec (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors CG Oncolgy
- 24 Sep 2021 New trial record
- 22 Sep 2021 According to a CG Oncolgy media release, the company has entered into a clinical trial collaboration agreement to evaluate the combination of CG0070, with Roche's atezolizumab. CG Oncology will sponsor the study and Roche will provide atezolizumab.